Pipeline
Discover our complex intranasal formulations and advanced drug-delivery solutions for chronic respiratory diseases and central nervous system disorders.
We develop a platform of drug-enabling solutions. Those long-acting intranasal solid dosage forms are designed to ensure a prolonged and targeted drug-delivery in chronic respiratory and Central Nervous System diseases.
- Formulation
- Phase 1
- Phase 2/3
- Market authorization
DIA01-R
Chronic allergic rhinitis
— Indicated for moderate to severe persistent allergic rhinitis. Resorbable fluticasone propionate-eluting insert delivering local treatment over 6 months
Addressable market: 1.4 B patients
DIA02-S
Chronic rhinosinusitis
— Indicated for Chronic Rhinosinusitis without polyps. Resorbable fluticasone propionate-eluting insert delivering local treatment over 12 months
Addressable market: 900 M patients
DIA03-N2BS
Nose-to-Brain — Schizophrenia
— Indicated for resistant schizophrenia. Exploratory program using the Nose-To-Brain route to deliver active compounds directly to the brain.
Addressable market: 35 M patients
